抗菌肽人β防御素3对肺炎克雷伯菌临床菌株的抑制作用研究

doi:10.3969/j.issn.1673-8640.2014.11.024

检验医学 ›› 2014, Vol. 29 ›› Issue (11): 1184-1187.DOI: 10.3969/j.issn.1673-8640.2014.11.024

抗菌肽人β防御素3对肺炎克雷伯菌临床菌株的抑制作用研究

张磊¹，印树葳²，张婷²，齐昕²，吕慧颖²，林萍¹

1. 上海交通大学医学院附属精神卫生中心，上海 200030；2. 上海交通大学医学院附属瑞金医院检验系，上海 200025

收稿日期:2014-07-15 出版日期:2014-11-01 发布日期:2014-11-28
作者简介:张磊，女，1981年生，学士，技师，主要从事临床医学检验工作。

Research on the inhibition on Klebsiella pneumoniae clinical isolates by antimicrobial peptide human β defensin 3

ZHANG Lei¹, YIN Shuwei², ZHANG Ting², QI Xin², LÜ Huiying², LIN Ping¹

1. Shanghai Mental Health Center, Shanghai Jiaotong University School of Medicine, Shanghai 200030, China;
2. Department of Laboratory Medicine, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China

Received:2014-07-15 Online:2014-11-01 Published:2014-11-28
Contact: 林萍,联系电话:021-64387250。

摘要/Abstract

摘要：

目的　分析抗菌肽人β防御素3（hBD3）对肺炎克雷伯菌临床分离株的抑菌作用。方法　合成抗菌肽hBD3，分别通过最低抑菌浓度（MIC）检测、直接杀菌试验、重要功能基因检测分析其对20株临床分离的肺炎克雷伯菌的直接抑制作用；并将其与阿莫西林、头孢他啶、环丙沙星联合应用，观察其对抗菌药物50%最低抑菌浓度（MIC50）和90%最低抑菌浓度（MIC90）的影响。结果　hBD3对20株肺炎克雷伯菌的MIC为（22.3±6.6）μg/mL；在浓度达到8 μg/mL时即有明显的杀菌作用。hBD3可上调ompC基因表达，下调yojL基因表达。在联用5 μg/mL hBD3后，头孢他啶、环丙沙星的MIC50和MIC90值均明显降低，而阿莫西林的MIC50和MIC90值无明显变化。结论　抗菌肽hBD3对肺炎克雷伯菌有明显的抑制作用，可望与抗菌药物联用治疗肺炎克雷伯菌感染。

关键词: 人β, 防御素3, 抗菌肽, 肺炎克雷伯菌, 抑菌试验

Abstract:

Objective　To analyze the inhibition effects of antimicrobial peptide human β defensin 3（hBD3） against Klebsiella pneumoniae clinical isolates. Methods　Antimicrobial peptide hBD3 was synthesized. The direct inhibition on 20 Klebsiella pneumoniae clinical isolates were detected by minimal inhibitory concentration（MIC） test， antibacterial activity test and the analysis on some important functional genes. The antimicrobial peptide was combined with amoxicillin， ceftazidime and ciprofloxacin for observing the effects on antibiotic 50% MIC（MIC50） and 90% MIC（MIC90）. Results　The MIC of hBD3 against Klebsiella pneumoniae clinical isolates was（22.3±6.6）μg/mL， the bactericidal activity was observed while hBD3 concentration was as high as 8 μg/mL. The hBD3 could improve the expression of ompC and reduce the expression of yojL.When 5 μg/mL hBD3 was added ， the MIC50 and MIC90 against Klebsiella pneumoniae clinical isolates of ceftazidime and ciprofloxacin were dropped down. Conclusions 　There is a considerable antibacterial activity of antimicrobial peptide hBD3 against Klebsiella pneumoniae clinical isolates. It could be used to inhibit Klebsiella pneumoniae infection combined with antibiotics.

Key words: Human &beta, defensin 3, Antimicrobial peptide, Antibacterial test

中图分类号:

R378

张磊，印树葳，张婷，齐昕，吕慧颖，林萍. 抗菌肽人β防御素3对肺炎克雷伯菌临床菌株的抑制作用研究[J]. 检验医学, 2014, 29(11): 1184-1187.

ZHANG Lei, YIN Shuwei, ZHANG Ting, QI Xin, LÜ Huiying, LIN Ping. Research on the inhibition on Klebsiella pneumoniae clinical isolates by antimicrobial peptide human β defensin 3[J]. , 2014, 29(11): 1184-1187.

参考文献

[1] Vikrant S, Guleria RC. Extended-spectrum beta-lactamase-producing Klebsiella pneumoniae causing peritonitis in a patient on continuous ambulatory peritoneal dialysis[J]. Saudi J Kidney Dis Transpl,2014,25(4):888-889.
[2] Fischetti VA. Phage antibacterials make a comeback[J]. Nat Biotechnol,2001,19(8):734-735.
[3] Parisien A,Allain B,Zhang J,et al. Novel alternatives to antibiotics:bacteriophages,bacterial cell wall hydrolases,and antimicrobial peptides[J]. J Appl Microbiol,2008,104(1):1-13.
[4] Jiang Y,Yang D,Li W,et al. Antiviral activity of recombinant mouse β-defensin 3 against influenza A virus in vitro and in vivo[J]. Antivir Chem Chemother,2012,22(6):255-262.
[5] Lee JK,Chang SW,Perinpanayagam H,et al. Antibacterial efficacy of a human beta-defensin-3 peptide on multispecies biofilms[J]. J Endod,2013,39(12):1625-1629.
[6] Schibli DJ,Hunter HN,Aseyev V,et al. The solution structures of the human beta-defensins lead to a better understanding of the potent bactericidal activity of HBD3 against Staphylococcus aureus [J]. J Biol Chem,2002,277(10):8279-8289.
[7] Clifford RJ,MilillO M,Prestwood J,et al. Detection of bacterial 16S rRNA and identification of four clinically important bacteria by real-time PCR[J]. PLoS One,2012,7(11):e48558.
[8] Domenech-Sanchez A,Benedi VJ,Martinez-Martinez L,et al. Evaluation of differential gene expression in susceptible and resistant clinical isolates of Klebsiella pneumoniae by DNA microarray analysis[J]. Clin Microbiol Infect,2006,12(9):936-940.
[9] 孙杰,徐炜新,时建英,等. 肺炎克雷伯菌的耐药性和防耐药突变浓度的初步研究[J]. 检验医学,2013,28(10):878-881.
[10] Dhariwal AK,Tullu MS. Colistin:re-emergence of the 'forgotten' antimicrobial agent[J]. J Postgrad Med,2013,59(3):208-215.
[11] Li Q,Zhou Y,Dong K,et al. Potential therapeutic efficacy of a bactericidal-immunomodulatory fusion peptide against methicillin-resistant Staphylococcus aureus skin infection[J]. Appl Microbiol Biotechnol,2010,86(1):305-309.
[12] Gould IM,Cauda R,Esposito S,et al. Management of serious meticillin-resistant Staphylococcus aureus infections:what are the limits[J]. Int J Antimicrob Agents,2011,37(3):202-209.
[13] Rice LB. Emerging issues in the management of infections caused by multidrug-resistant gram-negative bacteria[J]. Cleve Clin J Med,2007,74(Suppl 4):S12-S20.
[14] Wang G,Li X,Wang Z. APD2:the updated antimicrobial peptide database and its application in peptide design[J]. Nucleic Acids Res,2009,37(Database issue):D933-D937.

[1]	朱昱蓉, 张丹, 贺雅星, 李晶晶, 黄晶, 李婷, 刘鹏, 刘荣华. 肺炎克雷伯菌临床分离株分子分群和流行病学特征[J]. 检验医学, 2023, 38(5): 435-440.
[2]	王佳玮, 朱威南, 陈颖盈, 季萍, 王颖. 血培养分离碳青霉烯类耐药肺炎克雷伯菌临床分布和耐药基因分析[J]. 检验医学, 2023, 38(4): 362-367.
[3]	邓晨, 戴家泽, 邱丽红, 沈威廷, 蔡木发, 罗文英. 湛江地区高毒力肺炎克雷伯菌分子流行特征[J]. 检验医学, 2023, 38(11): 1026-1031.
[4]	杨思敏, 轩乾坤, 羽晓瑜, 温冬华, 李广波. 国产某品牌大肠埃希菌和肺炎克雷伯菌及3种碳青霉烯耐药基因试剂性能验证[J]. 检验医学, 2023, 38(1): 56-59.
[5]	王粟, 丁立, 姜文容, 缪应新, 张艳梅, 赵虎. 高毒力肺炎克雷伯菌耐药性和治疗策略研究进展[J]. 检验医学, 2023, 38(1): 81-86.
[6]	黄韵, 李从荣. 高毒力肺炎克雷伯菌研究进展[J]. 检验医学, 2021, 36(11): 1181-1185.
[7]	周燕霞, 金东芳. 单宁酸抑制肺炎克雷伯菌生物膜形成的作用及其机制[J]. 检验医学, 2021, 36(10): 1070-1073.
[8]	王军杰, 姚宗会, 马冰, 李轶, 闫文娟, 王山梅, 马琼, 袁有华. 碳青霉烯类耐药肺炎克雷伯菌致血流感染危险因素及预后分析[J]. 检验医学, 2020, 35(3): 195-199.
[9]	何丽华, 倪丽君, 杨思敏, 羽晓瑜, 周爱萍, 胡靓, 郭建, 吴文娟. RT-PCR快速检测产KPC型碳青霉烯酶肺炎克雷伯菌临床应用评价[J]. 检验医学, 2020, 35(10): 983-987.
[10]	温伟洪, 梁英健, 马芙蓉, 李玉珍, 徐令清. 耐碳青霉烯肠杆菌科细菌碳青霉烯酶检测与多位点序列分型分析[J]. 检验医学, 2019, 34(7): 577-582.
[11]	张保华, 余桂香, 江燕, 潘泓, 蒋翔宁. 2种常用肺炎克雷伯菌碳青霉烯类抗菌药物敏感性试验卡性能评价[J]. 检验医学, 2019, 34(3): 263-266.
[12]	张金花, 贺莉芳, 邓仁兵, 万启惠. 家蝇胚胎细胞抗菌肽对人髓样白血病细胞K562的杀伤作用[J]. 检验医学, 2019, 34(2): 173-175.
[13]	邹萍, 鲍俊峰, 臧嘉, 张婷, 许耀辉. 可视化LAMP法检测耐碳青霉烯酶肺炎克雷伯菌耐药基因bla_KPC-2的初步应用[J]. 检验医学, 2019, 34(1): 56-59.
[14]	管红艳, 刘瑛. 引起肝脓肿的肺炎克雷伯菌毒力因子研究进展[J]. 检验医学, 2018, 33(9): 839-843.
[15]	余佳佳, 刘婧娴, 李媛睿, 俞静, 刘瑛. 基质辅助激光解析电离飞行时间质谱快速检测ST11型产KPC-2肺炎克雷伯菌[J]. 检验医学, 2018, 33(6): 536-542.

抗菌肽人β防御素3对肺炎克雷伯菌临床菌株的抑制作用研究

Research on the inhibition on Klebsiella pneumoniae clinical isolates by antimicrobial peptide human β defensin 3

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics